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South Africa has high rates of HIV and HPV and high incidence and mortality from cervical
cancer. However, cervical cancer is largely preventable when early screening and treat-
ment are available. We estimate the costs and cost-effectiveness of conventional cytology
(Pap), visual inspection with acetic acid (VIA) and HPV DNA testing for detecting cases of
CIN2+ among HIV-infected women currently taking antiretroviral treatment at a public HIV
clinic in Johannesburg, South Africa.
Methods
Method effectiveness was derived from a validation study completed at the clinic. Costs
were estimated from the provider perspective using micro-costing between June 2013-April
2014. Capital costs were annualized using a discount rate of 3%. Two different service vol-
ume scenarios were considered. Threshold analysis was used to explore the potential for
reducing the cost of HPV DNA testing.
Results
VIA was least costly in both scenarios. In the higher volume scenario, the average cost per
procedure was US$ 3.67 for VIA, US$ 8.17 for Pap and US$ 54.34 for HPV DNA. Colpo-
scopic biopsies cost on average US$ 67.71 per procedure. VIA was least sensitive but most
cost-effective at US$ 17.05 per true CIN2+ case detected. The cost per case detected for
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Pap testing was US$ 130.63 using a conventional definition for positive results and US$
187.52 using amore conservative definition. HPV DNA testing was US$ 320.09 per case
detected. Colposcopic biopsy costs largely drove the total and per case costs. A 71% reduction
in HPV DNA screening costs would make it competitive with the conservative Pap definition.
Conclusions
Women need access to services which meet their needs and address the burden of cervical
dysplasia and cancer in this region. Although most cost-effective, VIA may require more fre-
quent screening due to low sensitivity, an important consideration for an HIV-positive popu-
lation with increased risk for disease progression.
Introduction
Cervical cancer is the most common cancer affecting women in Sub-Saharan Africa [1] and
the leading cause of cancer related death among females in the region [2]. Globally, cervical
cancer is the fourth most common cancer affecting women and accounts for 12% of all cancers
among women in resource-limited settings [1].
Approximately 90% of all cervical cancer cases are caused by persistent infection with high-
risk (oncogenic) type human papillomavirus (HPV) [3,4]. Most HPV infections resolve spon-
taneously within 1–2 years [5]. A study conducted in Brazil found that of women positive for
HPV at enrollment, just 35% were still positive 12 months later [6]. However, HIV infection is
a major risk factor for persistent HPV infection and abnormal cytological findings [7–10]. The
prevalence of atypical squamous cells of undetermined significance (ASCUS) and squamous
intraepithelial lesions (SIL) has been found to be 1.8 and 3.9 times greater respectively in HIV-
positive women than in HIV-negative women [8].
South Africa’s HIV and HPV infection rates are among the highest globally. Adult HIV
prevalence is 17.9% [11], and HPV prevalence ranges from 20.4% among women with normal
cytology to 83% in women with high-grade SIL [12]. The age-standardized rates of cervical
cancer incidence and mortality for the general population are 31.7 and 18.0 per 100,000 respec-
tively [1]. However, for HIV-positive women, invasive cervical cancer rates are much higher.
One treatment center in Gauteng Province documented a cervical cancer rate of 168 per
100,000 for women taking antiretroviral (ARV) therapy [13].
Early screening for cervical cancer allows for diagnosis of abnormalities at a pre-invasive
and treatable stage. Screening interventions currently available globally include conventional
and liquid based cytology (or a Papanicolaou (Pap) smear), visual inspection with acetic acid
(VIA), and HPV testing. Cytology and HPV testing require collection of a sample of cells and
“reading” or testing of the sample in a laboratory [14]. In resource limited settings, results are
usually only available days or weeks after the sample collection. In contrast, VIA, which
involves the application of dilute acetic acid to the cervix to visually identify lesions, can result
in an immediate diagnosis (i.e. during the procedure) [15].
Use of screening approaches varies globally and is often based on resource availability and
perceived cost effectiveness. In South Africa, according to national guidelines, all women
should have access to free cervical cancer screenings with conventional cytology in the public
sector at ten year intervals from age 30 to 50 [16]; HIV-positive women are allowed screening
upon diagnosis and then annually or three-yearly depending on the results of the initial and
subsequent screens [17].
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Most existing studies of the cost-effectiveness of cervical cancer screening rely on models
that draw input parameters from multiple and disparate sources [18–20]. Firnhaber et al.
recently validated the sensitivity and specificity of conventional cytology, VIA, and HPV DNA
testing for detection of cervical intra-epithelial lesion grade two or higher (CIN 2+) among
HIV-positive women taking ARV treatment at an HIV clinic in Johannesburg, South Africa
[13]. We collected data from the study site to estimate costs and evaluate the cost-effectiveness
of the screening methods used by Firnhaber et al for detecting cases of CIN2+ among the
cohort of HIV-infected women on treatment.
Materials and Methods
Effectiveness
Effectiveness was defined as detected cases of CIN2+. Sensitivity and specificity for detection of
this outcome by each screening method were derived from the validation study [13]. The study
was carried out at an HIV treatment clinic within a large, tertiary, public hospital in Johannes-
burg, South Africa from November 2009 to August 2011. HIV-infected women aged 18–65
were screened using the three alternative procedures: conventional cytology (or Pap), VIA, and
HPV DNA testing with Hybrid Capture (Qiagen). All women gave written consent to partici-
pate in the validation study and were screened with all three methods. Data used for the cost
evaluation were de-identified. A positive Pap result or positive VIA was followed by colpo-
scopic biopsy to allow for histological confirmation of the initial result by an anatomical
pathologist (Fig 1). Approximately 25% of the women with negative Pap smears and negative
VIA results also received colposcopic biopsy. HPV DNA results were received later and were
not used to determine whether colposcopic biopsy would be done.
Positive Pap results were defined in two ways in the validation study. The first definition
(Pap 1) followed current practice in the public sector. Positive results included: high grade SIL
(HSIL), “atypical squamous cells cannot rule out high grade lesion” (ASC-H), and squamous
cell carcinoma (SCC). Currently, women who are deemed positive by this definition are
referred for further diagnostics and/or treatment. To address the potential for increased risk of
progression to disease among HIV-positive women infected with HPV, a second definition
(Pap 2) was created for the validation study. With this definition a positive result was deemed
to include any non-negative result. Note that the procedure (and the associated cost) used for
Fig 1. Validation study design for detection of CIN in HIV-positive women. In the validation study, which preceded the study presented here, all women
were screened with all methods. After screening and diagnosis all women were followed up using study guidelines and local standards of care.
doi:10.1371/journal.pone.0141969.g001
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the Pap test was the same for Pap 1 and Pap 2. The difference was in the interpretation of the
results only.
Cost
Costs were estimated from a provider perspective. Data collection occurred between June 2013
and April 2014 at the same health facility that implemented the validation study. Staff time,
supplies, and equipment required per procedure were collected through discussions with the
clinic staff. At least three staff members provided input per procedure type. An average time
per procedure and average supply and equipment usage were then calculated using the three
responses unless there were large discrepancies in the reported information. For those cases,
staff were approached a second time to discuss the discrepancies and reach a consensus.
Unit costs for supplies and equipment were obtained from facility expenditure records or
other publicly available sources [21,22]. Personnel costs were drawn from public sector salary
scales [23]. National Health Laboratory Service (NHLS) service charges for 2012–2013 were used
to estimate laboratory costs, which included specimen transport costs and some consumables
including the glass slides, fixative and lab forms. Following generally recommended methods
[24], capital costs were annualized to obtain the equivalent annual cost using a discount rate of
3% and depreciation periods recommended for various categories of equipment by the South
Africa Revenue Service [25]. All costs were collected in South African Rand (R), inflated to 2013
prices (where necessary) using the South African Consumer Price Index [26], and are reported
here in 2013 US dollars using an average exchange rate for 2013 of 9.65 Rands per dollar [27].
Fixed costs such as infrastructure and utilities did not vary among the three screening meth-
ods and are not included in the analysis. All three screening services were offered by profes-
sional nurses who had received study-related training. The cost of this training is also not
included. Professional nurses learn to collect Pap smears as part of their four-year nursing
qualification in South Africa, so the cost of a professional nurse was used for collection of the
Pap smear. As collection of HPV DNA samples is very similar to collection of a Pap smear, the
cost of a professional nurse was also used for that service. VIA is not covered in professional
nurses’ education and would require extra training, thus for this analysis the cost of a nurse
with an additional two years of education, called a “primary health care (PHC) nurse,” was
used for the VIA service.
Analysis
Cost inputs were entered into a tool designed for this analysis in Microsoft Excel [28]. Using
the outcomes estimated in the validation study, the average cost per case of CIN2+ detected by
each screening strategy was calculated and compared taking into consideration both the costs
for the screening method alone and for colposcopic biopsy if required for women with positive
screening outcomes. Although positive VIA cases were followed with colposcopic biopsy in the
study for validation purposes, this would not occur in clinical practice in South Africa at pres-
ent and was not included in this cost-effectiveness analysis. Fig 2 illustrates the strategies
considered.
To explore the impact of scale on the cost and cost-effectiveness outcomes, two caseload sce-
narios were created. The Study Statistics scenario uses the average number of procedures actu-
ally done per day per nurse or doctor during the validation study. The Functional Limit
scenario represents the maximum number of procedures estimated to be possible per nurse or
doctor during an eight hour work day given the time required per procedure, which includes
time spent with each patient as well as daily, weekly and monthly tasks required for the service.
SI Tables contains further detail.
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Univariate sensitivity analysis was performed to explore the impact of variation in the cost-
ing inputs, service volumes and sensitivity and specificity of each procedure on cost effective-
ness. Average total costs were varied by 25% in each direction. Sensitivity and specificity were
varied using the confidence interval boundaries provided in the published report from the vali-
dation study.
Finally, HPV DNA testing is not currently available in the public sector in South Africa. In
consideration of the potential for its introduction, threshold analysis was used to determine the
necessary reduction in costs required to make this novel approach competitive with the cur-
rently offered conventional cytology service.
Ethics approval for all data collection and analysis was obtained from the Human Ethics
Research Committee at the University of the Witwatersrand. The Consolidated Health
Fig 2. Strategies for cost-effectiveness analysis comparing cervical screeningmethods. Colpo. = colposcopic biopsy, LSIL = low grade squamous
intraepithelial lesions, ASCUS = atypical squamous cells of undetermined significance, ASC-H = atypical squamous cells cannot rule out high grade lesion,
HSIL = high grade squamous intraepithelial lesions, SCC = Squamous cell carcinoma
doi:10.1371/journal.pone.0141969.g002
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Economics Evaluation Reporting checklist, a standardized, internationally recognized tool, was
used in the preparation of this manuscript [29].
Results
Screening services
The resources required to provide screening are summarized in Table 1. The VIA service
included painting and viewing the cervix. The nurse also photographed the cervix, and in a
weekly quality control meeting the photographs and diagnoses were reviewed by a team of
nurses and doctors. Colposcopic biopsy was performed by a medical officer with assistance
from a staff nurse. Cytology slides and histology specimens were sent to the NHLS as per stan-
dard of care for processing. Medical officers reviewed all Pap results when received from the
NHLS and provided instruction on whether to call back the women for follow up. If a woman
returned for her results, these were provided by a professional nurse and/or medical officer.
Counsellors were available to provide extra counselling and information if needed. HPV DNA
samples were sent to a special lab at the University of Cape Town, and results were emailed
back to the study team.
Screening costs
The costs for screening include both service-level and per procedure inputs. Service-level
inputs include equipment, certain supplies and elements of staff time. For example, the time
spent each day gathering the necessary supplies, setting up and cleaning the clinic rooms, and
filling out the necessary paperwork was constant regardless of the number of procedures
Table 1. Resources utilized to provide screening services.
Resource Details
Personnel*
Staff nurse Retrieved the day’s supplies, set up the rooms, etc. Assisted with colposcopic
biopsies.
Professional nurse Performed Pap and HPV DNA sample collection, provided screening results.
PHC nurse Cost used for VIA screening and participation in weekly VIA quality control meeting.
Medical officer Reviewed all Pap results, provided instruction on whether to call back the women
for follow up, assisted in provision of results as needed. Performed colposcopic
biopsies.
Counselor Assisted in calling back women and scheduling return visits if needed.
Supplies and equipment
Supplies Gloves, masks, linen savers, cotton swabs, paper towels, hand washing/sanitizing
supplies, pens/pencils, forms, files, sanitary towels, acetic acid, paper towels.
Furnishings Two rooms for screening and one for colposcopic biopsy procedures contained
desks, chairs, examination beds, trolleys, and other medical furnishings.
Other equipment Speculum, metal receiving dishes, colposcope machine, punch biopsy forceps,




Lab fee which included cytology collection spatula, slides, fixative, specimen vials,
formalin, lab forms and materials for shipment to/from lab.
HPV DNA analysis Hybrid capture II sample collection kit, courier fee, lab testing fee.
PHC nurse = Primary health care nurse
*Training for the nurses is as follows: Staff nurse, 2 years; Professional nurse, 4 years; PHC nurse, 6
years.
doi:10.1371/journal.pone.0141969.t001
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performed. In contrast, staff time, lab fees and most supply usage varied depending on the
number of procedures performed.
Table 2 provides information about the two caseload scenarios considered when estimating
the cost per procedure. In the Study Statistics scenario, the same number of procedures was
done per day for each screening method—roughly two procedures per day per nurse for
screening and roughly three colposcopic biopsies per day per medical officer. In the Functional
Limit scenario, the procedures possible per eight hour work day per nurse increased to 12.6
Paps, 11.6 VIA’s, or 14.2 HPV DNA tests. Also under this scenario, it is estimated that the
medical officers could do as many as 22.7 colposcopic biopsies per day. The number of proce-
dures theoretically possibly in this second scenario might not be practical given the interrup-
tions expected in a typical work day; however it is helpful to consider them as an upper
boundary.
Table 3 provides the average total cost per screening procedure given the two service volume
scenarios. The base case results and a range representing 25% higher and lower costs are pre-
sented for personnel, supplies, equipment, lab and total costs. The costs were higher for all pro-
cedures under the Study Statistics scenario than under the Functional Limit scenario where
volumes were higher. In both scenarios, VIA was the least costly of the three screening options
at an average total cost of US$ 3.67 (2.76–4.59) under the Functional Limit scenario and US$
9.12 (6.84–11.40) under the Study Statistics scenario. Pap testing cost US$ 8.17 (6.13–10.22)
and US$ 12.55 (9.41–15.68) under the two respective scenarios; and HPV DNA testing was
most expensive at US$ 54.34 (40.75–67.92) and US$ 58.61 (43.96–73.26). The difference in
costs was largely explained by lab costs, which comprised the majority of the Pap and HPV
DNA testing costs. VIA services do not require any external laboratory testing. HPV DNA lab
costs were particularly high at US$ 51.74 (38.80–64.67) per test, or 95.2% of the total proce-
dural cost. This high cost was likely because the test was performed by an academic lab during
the study and was not yet available in the public sector. Colposcopic biopsy costs were US$
67.71 (50.79–84.64) under the Functional Limit scenario and US$ 75.04 (56.28–93.80) under
the Study Statistics scenario.
Cost effectiveness
As published previously, 1,202 women underwent the three screening strategies under investi-
gation in the validation study; 1,193 were included in the analytic cohort and cost effectiveness
analysis. As indicated in Table 4, the cost of screening this population with the initial screening
method only was US$ 4,383 with VIA, US$ 9,750 for Pap and US$ 64,826 with HPV DNA test-
ing. The “true prevalence” of CIN2+ in the study population, calculated based on colposcopic
biopsy results, was 32.94% (95% confidence interval 30.01–36.01) or 393 cases [13]. As indi-
cated in Table 4, given this prevalence and the published sensitivity and specificity information,
Table 2. Caseload scenarios: Total procedures possible per day per study nurse or doctor.
Scenario Pap VIA HPV Colposcopic biopsy
Professional nurse PHC nurse Professional nurse Medical officer with assistance from staff nurse
Study Statistics* 1.9 1.9 1.9 3.3
Functional Limit** 12.6 11.6 14.2 22.7
*Average number of procedures done in the clinic during the study timeframe (i.e. average per nurse/doctor per day).
**Calculated using the reported time required per procedure plus time required for daily, weekly and monthly activities directly required by each service. It
assumes 8 hours of productive time per work day.
doi:10.1371/journal.pone.0141969.t002
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using the Pap 2 definition, cytology would have identified 888 positive cases (i.e. all abnormal
results) (373 true positive, 515 false positive). HPV DNA testing resulted in detection of 750
positive cases (361 true positive, 389 false positive). The Pap 1 definition identified 431 cases
(298 true positive, 133 false positive), and VIA identified 509 cases (257 true positive, 252 false
positive).
For Pap 1, Pap 2 and HPV DNA screening, all positive cases incurred the additional cost of
colposcopic biopsy. The total cost of screening, i.e. the cost of the initial screening method plus
the colposcopic biopsy for screen positive cases, was US$ 38,915 for Pap 1, US$ 69,865 for Pap
2, and US$ 115,610 for HPV DNA testing. The total cost of screening for VIA was the cost of
initial screening only—US$ 4,383. The false positives identified by Pap 1, Pap 2 and HPV DNA
screening were responsible for 23.1%, 49.9% and 22.8% of the total costs respectively.
Finally, considering the cost per true positive CIN2+ case detected, VIA was least expensive
with an average cost of US$ 17.05 per case. Pap 1 was US$ 130.63 per case; Pap 2 was US$
187.52 per case; and HPV DNA screening was most costly at US$ 320.09 per case.
Comparing the incremental cost effectiveness of the four approaches, HPV DNA screening
was “dominated” by Pap 2 in that HPV DNA testing offered fewer true cases while costing
more overall. Then comparing VIA, Pap 1 and Pap 2, Pap 1 was dominated by Pap 2 in that
Table 3. Average estimated procedure costs for each scenario (USD 2013), cost ranges for sensitivity analysis.
Functional Limit Study Statistics**
Cost (Range)* % of total Cost (Range)* % of total
Pap
Personnel 1.43 (1.08–1.79) 17.6 2.64 (1.98–3.30) 21.0
Supplies 1.03 (0.77–1.29) 12.6 1.40 (1.05–1.76) 11.2
Equipment 0.50 (0.37–0.62) 6.1 3.30 (2.47–4.12) 26.3
Lab/transport 5.21 (3.91–6.51) 63.7 5.21 (3.91–6.51) 41.5
Total 8.17 (6.13–10.22) 100.0 12.55 (9.41–15.68) 100.0
VIA
Personnel 1.56 (1.17–1.95) 42.5 2.10 (1.57–2.62) 23.0
Supplies 1.24 (0.93–1.55) 33.7 1.71 (1.28–2.14) 18.8
Equipment 0.88 (0.66–1.09) 23.8 5.32 (3.99–6.64) 58.3
Lab/transport 0.00 (0.00–0.00) 0.00 0.00 (0.00–0.00) 0.0
Total 3.67 (2.76–4.59) 100.0 9.12 (6.84–11.40) 100.0
HPV DNA
Personnel 1.39 (1.04–1.73) 2.5 2.36 (1.77–2.95) 4.0
Supplies 0.76 (0.57–0.95) 1.4 1.14 (0.85–1.42) 1.9
Equipment 0.46 (0.34–0.57) 0.8 3.38 (2.54–4.23) 5.8
Lab/transport 51.74 (38.80–64.67) 95.2 51.74 (38.80–64.67) 88.4
Total 54.34 (40.75–67.92) 100.0 58.61 (43.96–73.26) 100.0
Colposcopic biopsy
Personnel 2.10 (1.58–2.63) 3.1 2.26 (1.70–2.83) 3.0
Supplies 1.50 (1.12–1.87) 2.2 2.84 (2.13–3.55) 3.8
Equipment 1.00 (0.75–1.25) 1.5 6.83 (5.12–8.53) 9.1
Lab/transport 63.11 (47.33–78.89) 93.2 63.11 (47.33–78.89) 84.1
Total 67.71 (50.79–84.64) 100.0 75.04 (56.28–93.80) 100.0
*Range represents 25% lower and higher than base case. These boundaries were used for the sensitivity analysis.
**The Study Statistics estimates were also explored in the sensitivity analysis.
doi:10.1371/journal.pone.0141969.t003
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the marginal cost of identifying true CIN2+ cases was higher when compared to VIA. Table 5
provides the Incremental Cost Effectiveness Ratios (ICERs) for the final comparison. Fig 3
illustrates the cost effectiveness “frontier” when comparing the four approaches for HIV-posi-
tive women on ARV treatment. Again, VIA and Pap 2 are the dominant options.
In the sensitivity analysis, the comparison of total costs and ranking of methods did not
change when the costs for each screening procedure varied by 25 percent higher or lower or for
the different service volume scenarios. Changing the sensitivity and specificity data to the
extent indicated in the 95% confidence intervals published for the validation study (and pre-
sented in Table 4) also did not change the ranking of the methods except for in one case.
Increasing the sensitivity of HPV DNA screening to the higher bound of the confidence inter-
val (i.e. to 95.3%) meant that this method was then more sensitive than Pap 2 and identified
more true positive cases. However these cases still came at a higher cost of US$ 311.08 per case
detected (as compared to US$ 187.52 for Pap 2).
Table 4. Screening outcomes, costs for screening analytic cohort for CIN 2+ (Functional Limit scenario).
Pap 1 Pap 2 VIA HPV DNA
Sensitivity and specificity (95% CI) [13]
Sensitivity 75.8% (70.8–
80.8)
94.8% (90.5–99.2) 65.4% (59.7–71.1) 91.9% (88.5–95.3)
Specificity 83.4% (80.9–
85.9)





431 (430–431) 888 (879–898) 509 (506–512) 750 (736–764)
TP (95%
CI)
298 (278–318) 373 (356–390) 257 (235–279) 361 (348–375)
FP (95%
CI)




95 (75–115) 20 (3–37) 136 (114–158) 32 (18–45)
Screening costs (US $)*
Initial screen 9,750 (7,313–
12,188)











69,865 (52,922–86,561) 4,383 (3,287–5,478) 115,610 (87,410–143,341)
% of total cost
spent on
colpo. for FP’s






187.52 (148.79–222.02) 17.05 (14.01–19.61) 320.09 (251.31–382.71)
CI = Confidence interval, TP = True positive, FP = False positive, FN = False negative, Colpo. = colposcopic biopsy
*All costs are presented with a range of 25% higher and lower.
**Considers the colposcopic biopsy costs for true positives plus false positives. Not clinically relevant for VIA.
***For initial screen plus colposcopic biopsy when indicated. Excludes colposcopic biopsy for VIA because not clinically relevant.
doi:10.1371/journal.pone.0141969.t004
Cost Effectiveness of Cervical Cancer Screening in HIV-Positive Women
PLOSONE | DOI:10.1371/journal.pone.0141969 November 16, 2015 9 / 16
As noted above, HPV DNA testing is not currently available in the public sector in South
Africa. Reducing the lab costs required for the test to US$ 1.00 would reduce the total cost per
screen to US$ 3.60 and reduce the cost per true case of CIN2+ detected to US$ 152.51. How-
ever, due to the higher sensitivity and lower specificity of HPV DNA testing as compared to
Pap 1 among HIV-positive women, the cost per true case detected is still higher with HPV
DNA testing than for Pap 1. In fact, due to the higher number of false positive cases identified
and the cost of colposcopic biopsies for these cases, even reducing the lab costs for HPV DNA
testing to zero, HPV DNA testing is still more expensive per true CIN2+ case identified than
Table 5. Incremental cost-effectiveness analysis (Functional Limit scenario).
Total Incremental ICER
True cases detected Cost* True cases detected Cost
No screening 0 0 — — —
VIA alone 257 4,383 257 4,383 17
Cytology (Pap-1) plus colpo. 298 38,915 Dominated*** Dominated*** —
HPV DNA plus colpo. 361 115,610 Dominated** Dominated** —
Cytology (Pap-2) plus colpo. 373 69,865 116 65,482 567
ICER = Incremental cost-effectiveness ratio, colpo. = colposcopic biopsy
*For initial screen plus colposcopic biopsy when indicated. Excludes colposcopic biopsy for VIA because not clinically relevant.
**HPV DNA screening was dominated by Pap 2 in that it offered fewer cases for a higher total cost.
***Pap 1 was dominated by Pap 2 in that the marginal cost of identifying cases was higher than with Pap 2.
doi:10.1371/journal.pone.0141969.t005
Fig 3. Comparison of screeningmethods: True cases of CIN2+ detected by cost per case.NB: The line represents the cost-effectiveness threshold, or
frontier. All interventions or combinations of interventions along this line are more cost effective than intervention or combination of interventions left of the
line.
doi:10.1371/journal.pone.0141969.g003
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Pap 1. Pap 2 was put forward in the validation study as a hypothetical, alternative screening
approach for HIV-positive women on ARV treatment. However, it is important to note that
the Pap 2 option is currently not allowed within the national screening guidelines. In the incre-
mental analysis provided in Table 5, Pap 2 offered more true cases for less cost and thus “domi-
nated” the HPV DNA option. However, if the lab costs for HPV DNA testing were reduced by
roughly 75% to US$ 12.93 (resulting in a 71% reduction of the total screening cost to US$
15.54), the average total cost per case detected would then be US$ 191.92, and HPV DNA test-
ing would no longer be dominated by the hypothetical Pap 2 approach (Table 6).
Discussion
Considering VIA, HPV DNA, Pap 1 and Pap 2 as four cervical cancer screening approaches for
HIV-positive women on ARV treatment, VIA was most cost effective at US$ 17.05 per true
case of CIN2+ detected. However, due to its lower sensitivity and specificity, using VIA
resulted in a high number of missed diagnoses (i.e. false negative results). The hypothetical Pap
2 alternative (i.e. any abnormal Pap smear) had the highest sensitivity and lowest specificity of
all the approaches and resulted in the highest number of true cases being detected, albeit with a
large number of women having unnecessary colposcopic biopsies because all non-negative Pap
results were considered positive. Colposcopic biopsy was relatively expensive, costing almost
US$ 70 per procedure. When the cost of colposcopic biopsy as a follow up for screen positive
cases was added for Pap 1, Pap 2 and HPV DNA screening, the total cost for screening was
highest for HPV DNA screening at US$ 115,610 for the analytic cohort of 1,193 women. Col-
poscopic biopsy was clinically irrelevant for VIA as diagnosis and treatment could be provided
the same day, so the total cost for screening was lowest with VIA and represented the initial
screening cost only, i.e. US$ 4,383.
Currently in South Africa, conventional cytology using the Pap 1 definition as presented
here is the screening method offered in the public sector for both HIV-negative and HIV-posi-
tive women. This analysis suggests that VIA might be a more cost-effective approach for
screening HIV-positive women; however, there are several important issues for consideration.
First, as noted above, VIA is less specific than the other three approaches, potentially resulting
in more overtreatment. “Overtreatment” with VIA assumes that cryotherapy would be a viable
treatment option and be offered the same day; whereas “overtreatment” with the other meth-
ods might involve unnecessary colposcopic biopsies. To understand the trade-off presented
here, one would need to compare the risks and costs of overtreatment with cryotherapy versus
Table 6. Threshold analysis comparing the costs of HPV DNA testing to actual and hypothetical Pap screening (Functional Limit scenario).
HPV DNA versus Pap 1 HPV DNA versus Pap 2
Pap 1 HPV DNA Pap 2* HPV DNA
Screening cost reduced to:
Lab cost (US$) No change 1.00 No change 12.93
Total cost (US$) No change 3.60 No change 15.54
True cases detected 298 361 373 361
Total cost for screening** 38,915 55,083 69,865 69,320
Cost per true case detected 130.63 152.51 187.52 191.92
* Note that this method is not currently allowed under existing guidelines, but was presented as a hypothetical alternative in the validation study.
** For initial screen plus colposcopic biopsy when indicated. Excludes colposcopic biopsy for VIA because not clinically relevant.
doi:10.1371/journal.pone.0141969.t006
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the risks and costs of the unnecessary colposcopic biopsies that would follow the other screen-
ing approaches.
Second, VIA is also less sensitive for CIN2+ detection than the other three approaches,
resulting in more missed cases. Clearly missing a diagnosis has serious implications, especially
among HIV-positive women who are at increased risk for progression and less likely to have
disease regression [9]. However, it is important to remember that the analysis presented here
was conducted within a study setting where there were no barriers to access or reduced loss to
follow up for any service. This is not the case in South Africa’s public sector. Similar to many
other low and middle income country settings, South Africa’s public sector is plagued by high
numbers of inadequate cervical smears, often as the result of poor collection techniques [30].
Women with inadequate smears must be called back for a repeat test, presenting an opportu-
nity for loss to follow up. For women who do receive a positive, or abnormal, Pap result, many
do not return for colposcopic biopsy. Data are lacking on the exact magnitude of the problem,
but it is known anecdotally to be significant and in large part caused by service limitations.
Loss-to-follow-up problems are not unique to South Africa, and have been shown to be crit-
ical for bigger-picture comparisons of screening methodologies. In 2005, Goldie et al, used
modelling to determine that screening strategies requiring fewer visits and less opportunity for
loss to follow up were most cost-effective when considering lifetime risk of cancer, years of life
saved, lifetime costs, and cost-effectiveness ratios. They determined that for five developing
country locations, including South Africa, once in a lifetime screening with VIA or HPV DNA
testing followed by immediate cryotherapy reduced lifetime risk of cancer by roughly 25–36%
and cost less than $500 per life year saved [19].
Concerns about VIA’s sensitivity and specificity could possibly be assuaged through train-
ing and regular quality assurance activities. In Firnhaber et al’s (2013) validation study, they
present sensitivity and specificity data for VIA performed by nurses as well as doctors [13].
Although the performance was comparable and global VIA recommendations do specify that
the service can be safely offered by nurses [31], the sensitivity and specificity outcomes for the
doctors were higher [13]. If nurses’ outcomes could be improved over time through practice
and quality management efforts including a second review via digital cervicography [32],
missed cases and overtreatment may be reduced. Note that this added quality assurance cost
was not included in this analysis.
The hypothetical Pap 2 approach for screening, which classified any abnormal result as pos-
itive and requiring colposcopic biopsy, was also competitive in the incremental cost-effective-
ness analysis. This approach casts a “wide net” and identifies almost all of the true cases in the
analytic cohort; however, many women also receive false positive diagnoses. For HIV-positive
women with increased risk of disease progression, perhaps the “wide net” approach is accept-
able to avoid missing cases. HPV DNA testing is also highly sensitive and offers greater speci-
ficity than the Pap 2 option, but it was also very expensive under the study conditions. In the
threshold analysis, with a 71% reduction in the costs of the lab component of the HPV DNA
screening cost, this approach became a competitive alternative as compared to the Pap 2
approach. Economies of scale and/or new technologies may offer opportunities for lowered
costs. Point-of-care (POC) technologies for HPV testing are currently being validated in South
Africa and may help to eliminate expensive lab costs. Initial outlays for POC technologies are
often high, and significant volumes would likely need to be guaranteed to ensure competitive
pricing with this approach. However, at least one new POC option (Xpert) is currently becom-
ing more available in areas with HIV prevalence due to its use in tuberculosis screening [33].
This machine uses self-contained testing cartridges, and the manufacturer offers a range of
options, including testing for sexually transmitted infections and HPV [34].
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Comparing HPV DNA testing with the currently available Pap 1 approach, it is important
to consider that the total cost of screening for these two approaches (and Pap 2) are largely
driven by the costs of colposcopic biopsy. Because HPV DNA testing is more sensitive and less
specific than the Pap 1 approach, it results in more women undergoing colposcopic biopsy in
this analysis. The extra cost for those additional women is so great that, even if HPV DNA
screening costs were dropped to zero, it would remain a more costly approach in this analysis.
Limitations
This analysis has its limitations. Considering the cost outcomes, training and overhead were
not included, and retrospective collection of data within a study setting was challenging. How-
ever, the cost of the nurse for the screening procedures was varied to address the nursing edu-
cation/qualification requirements of the procedures, and data were collected from at least three
individuals in an attempt to reduce recall bias. Other unit costs are available in the literature
but are difficult to compare given variation in the methods used to collect the costs. To our
knowledge, the work presented here is the only full micro-costing of cervical cancer screening
in South Africa. Others have depended all or in part on South Africa’s Uniform Patient Fee
Schedule to obtain unit costs and may not accurately reflect costs to the health system
[18,20,35].
Also, this analysis stops at diagnosis of CIN2+ and does not consider the cost of treating
women with dysplasia or cervical cancer or the potential for cancer-related mortality. Further,
the time horizon stops at identification of cases and does not consider the long term repercus-
sions of missed cases, or false negatives. Similarly, loss to follow up between screening and col-
poscopic biopsy was not included as this was not a significant issue within the validation study
setting. Future analyses should consider longer time horizons, the potential for loss to follow
up and the cost of treatment (cryotherapy or other alternatives).
Despite these limitations, our results are similar to other published cost-effectiveness analy-
ses from South Africa in that strategies which eliminate or reduce the need for follow up visits
and/or expensive colposcopy seem most competitive. In 2001, Goldie et al considered lifetime
costs and benefits, including those associated with treating cancer if found, and concluded that
HPV or VIA followed by same day treatment was most cost effective [18]. In a separate model-
ling exercise from 2005, Goldie et al recommended HPV DNA testing again followed by same
day treatment [35], and in 2009, Vijayaraghavan et al recommended conventional cytology fol-
lowed by HPV DNA testing for triaging rather than colposcopic biopsy [20].
Conclusion
Despite its limitations, this study provides locally collected cost data for three cervical dysplasia
screening methods and cost effectiveness data for four screening approaches. In low-resource
settings, such as South Africa, with a high burden of high-risk HPV and HIV, cost-effective
strategies for cervical cancer screening are necessary if limited resources are to be used effec-
tively. In South Africa, national strategic documents indicate an aim of 70% coverage for the
current Pap services; however, actual coverage falls short. For 2010–2011, based on ten-yearly
screening intervals, coverage was estimated to be 52% [36]. Locally collected cost and cost
effectiveness data are important for local policymakers charged with improving these statistics.
Ultimately women need access to services which meet their needs and address the signifi-
cant burden of cervical dysplasia and cancer in this region. In many resource limited settings,
improving existing Pap services is a goal for addressing this need, which is particularly urgent
among HIV-positive women. However, alternatives exist. VIA offers the ability for same day
diagnosis and treatment, minimizing loss to follow up. Zambia’s national screening program is
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based on VIA and may be seen as a model for other, similar settings [37]. Alternatively, shifting
to either a more conservative definition for triaging Pap results (i.e. the hypothetical Pap 2 defi-
nition) or HPV DNA testing could improve case detection, but not without increased costs.
This analysis offers insight regarding the costs of three screening alternatives; however, ulti-
mately the budget and priorities within the health system must dictate the methods selected.
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